### Fiscal Year 2019 Melanoma Research Program
**Reference Table of Award Mechanisms and Submission Requirements**

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Concept Award** | Investigators at or above postdoctoral fellow (or equivalent). | • Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in melanoma.  
• Emphasis is on innovation.  
• Preliminary data are strongly discouraged.  
• Clinical trials are not allowed.  
• Blinded review. | • The maximum period of performance is 1 year.  
• The maximum allowable funding for the entire period of performance is **$75,000** in direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | **Pre-Application (Letter of Intent):**  
October 2, 2019  
5:00 p.m. Eastern time (ET)  
**Application:**  
October 23, 2019  
11:59 p.m. ET |
| **Idea Award** | Independent investigators with a faculty-level appointment (or equivalent). | • **Preproposal is required; application submission is by invitation only.**  
• Supports new ideas that represent innovative, high-risk, high-gain approaches to melanoma research.  
• Emphasis on innovation and impact.  
• Preliminary data are not required.  
• Clinical trials are not allowed. | • The maximum period of performance is 3 years.  
• The maximum allowable funding for the entire period of performance is **$300,000** in direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | **Pre-Application:**  
July 26, 2019  
5:00 p.m. ET  
**Application:**  
October 23, 2019  
11:59 p.m. ET |
Go to:
- Program Announcement
- General Application Instructions

Grants.gov Funding Opportunity Number: W81XWH-19-MRP-TSA

**Eligibility**

At least two and up to three investigators must partner in one overarching multidisciplinary research study.

**Initiating Principal Investigator (PI):**
Independent investigators at or above the level of Associate Professor (or equivalent).

**Partnering PI:** Independent investigators at or above the level of Assistant Professor (or equivalent).

**Post-doctoral fellows are not eligible to be partnering PIs.**

**Key Mechanism Elements**

- **Preproposal is required; application submission is by invitation only.**
- Supports new or existing partnerships between two or three independent investigators focusing research across the whole research spectrum.
- Investigators are expected to demonstrate, within the application, the synergistic components (i.e., leveraging disciplines, expertise, or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through independent efforts of a single investigator.
- Emphasis on synergy, multi-disciplinary research, and impact.
- Inclusion of an independent early career investigator is encouraged.
- Inclusion of at least one military or U.S. Department of Veterans Affairs (VA) investigator is encouraged.
- Preliminary data are required.
- Clinical trials are not allowed.

**Funding**

- The maximum period of performance is 3 years.
- The maximum allowable funding for the entire period of performance is $700,000 in direct costs.
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

**Submission Deadline**

**Pre-Application:**
July 26, 2019
5:00 p.m. ET

**Application:**
October 23, 2019
11:59 p.m. ET
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Translational Research</td>
<td>Independent investigators at or above the level of Assistant Professor (or</td>
<td>● Preproposal is required; application submission is by invitation only.</td>
<td>● The maximum period of performance is 3 years.</td>
<td>Pre-Application:</td>
</tr>
<tr>
<td>Award</td>
<td>equivalent).</td>
<td>● Supports studies aiming to leverage existing biobanks, biorepositories, ongoing or</td>
<td>● The maximum allowable funding for the entire period of performance is</td>
<td>July 26, 2019 5:00 p.m. ET</td>
</tr>
<tr>
<td></td>
<td></td>
<td>completed clinical trials to address a translational question or problem in melanoma.</td>
<td>$600,000 in direct costs.</td>
<td>Application:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Emphasis on translation and impact.</td>
<td></td>
<td>October 23, 2019 11:59 p.m. ET</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Inclusion of Department of Defense or VA participation is encouraged.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Preliminary data are required.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Clinical trials are not allowed.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Grants.gov Funding Opportunity Number:**
W81XWH-19-MRP-TRA